Kornimate/medical-research-clean huggingface dataset:
intraperitoneal irinotecan with concomitant folfox and bevacizumab

Conditions: Colorectal Cancer; Peritoneal Metastases

Summary: the rationale of the current study is that the addition of intraperitoneal irinotecan (75 mg) to palliative systemic therapy is feasible and safe, and might result in an increased overall and progression free survival in patients with unresectable colorectal peritoneal metastases. the primary objectives are to explore the overall survival for the addition of intraperitoneal irinotecan (75 mg) to palliative systemic therapy in patients with unresectable colorectal peritoneal metastases. secondary objectives are to assess the progression-free survival, toxicity profile, patient reported outcomes, costs, tumor response during trial treatment, and the systemic and intraperitoneal pharmacokinetics of irinotecan and sn-38. this is a single-arm, open-label, phase ii study and patients will receive intraperitoneal irinotecan (75 mg) in combination with modified folfox4 + bevacizumab.


Eligibility criteria:
inclusion criteria: * histologically confirmed colorectal cancer; * radiologically and clinically or pathologically confirmed unresectable colorectal peritoneal metastases (e.g. pci \>20, extensive small bowel involvement, unresectable disease due to anatomical location); * who performance score of 0-1 with a life expectancy of \>3 months; * aged 18 years or older; * written informed consent; exclusion criteria: * presence of extensive systemic metastases that are deemed to be the dominant factor determining prognosis in terms of life expectancy and performance status \[e.g. no imminent threat of impaired organ functioning due to the presence of systemic metastases\]); * prior cytoreductive surgery; * prior palliative systemic therapy for colorectal cancer; * prior neo-adjuvant/adjuvant systemic therapy for colorectal cancer within the last 6 months; * homozygous ugt1a1\*28 genotype; * homozygous dihydropyrimidine dehydrogenase (dpd) deficiency * microsatellite instable (msi) primary tumor * any contra-indication for the planned chemotherapy (e.g. active infection, serious concomitant disease, severe allergy), as determined by the medical oncologist; * inadequate organ functions, defined as an haemoglobin of \ 1.5 x uln, creatinine clearance of \ 2x uln and liver transaminases of \>5 x uln.

Keywords: peritoneal metastases colorectal cancer intraperitoneal irinotecan
the effect of body mass index and total cholesterol levels on histopathological grading in breast cancer patients

Conditions: Breast Cancer

Summary: breast cancer is a widespread cancer that affects high percentiles of women worldwide.the development and aggressiveness of breast cancer cells can be evaluated depending on the histopathological grading which reflects the degree of differentiation. several factors related to lifestyle can impact the development of breast cancer. obesity is an important factor that received the attention in recent years. the using of body mass index(bmi) is still the common method for identifying obesity which is defined when having 30kg/m² or more. previous epidemiological and clinical studies found that obesity was correlated with advanced breast cancer especially in postmenopausal patients . also, the changes in cholesterol levels can influence breast cancer risk in the context of obesity. the findings of other studies is still controversial; many studies revealed that elevated total cholesterol levels could increase breast cancer risk while others found to have no effect. due to the possibility of previous factors' effect on breast cancer progression, we purposed in this study to assess the association of bmi and total cholesterol with histopathological grading according to menopausal status among a group of breast cancer patients in syria


Eligibility criteria:
inclusion criteria: all participants after ensurement that all their clinical and demoghraphical data are completed exclusion criteria: metabolic syndromes, as well as patients with statin therapy and hormonal replacement treatment.
spray diathermy versus harmonic scalpel technique for hepatic parenchymal transection

Conditions: End Stage Liver Disease

Summary: consecutive patients, who were treated for end stage liver cirrhosis by ldlt were included in this a prospective study.patients enrolled in the study divided into two groups according to the day of surgery. the study population was divided into two groups; group (a) parenchymal liver transection was performed by harmonic scalpel (hs) and group (b) parenchymal liver transection was performed by spray diathermy (sd).

consecutive patients, who were treated for end stage liver cirrhosis by ldlt were included in this a prospective study.patients enrolled in the study divided into two groups according to the day of surgery. the study population was divided into two groups; group (a) parenchymal liver transection was performed by harmonic scalpel (hs) and group (b) parenchymal liver transection was performed by spray diathermy (sd). donors and recipient were followed up after hospital discharge with laboratory investigation, abdominal ultrasound, mrcp in selected cases every month for the first month, then every 6 months and then every year postoperatively. follow up visits included clinical examination, laboratory investigation, doses of immunosuppressive, radiological examination, and doppler us. the primary outcome was the amount of blood loss during transection. secondary outcomes were operative time, time of transection, speed of transection/minutes , number of ligation used, degree of postoperative injury which assessed by daily liver function, wbc, c reactive protein, pathological changes at the cut surface, postoperative morbidity (including biliary leakage, collection), cost and hospital stay.

Eligibility criteria:
inclusion criteria: consecutive patients, who were treated for end stage liver cirrhosis by ldlt exclusion criteria: -

Keywords: living donor liver transplantation
enhancing physical and cognitive efficiency in individuals at risk of dementia using whole-body electromyostimulation

Conditions: Mild Cognitive Impairment

Summary: this study aimed to evaluate the effectiveness of twelve weeks whole-body electrical muscle stimulation combined with aerobic exercises.

this study aimed to evaluate the effectiveness of twelve weeks of wb-ems (whole-body electrical muscle stimulation at 35hz and 350 μs) combined with aerobic exercises on a treadmill and rowing machine, in improving physical and cognitive performance in older adults, both healthy and at risk of dementia. the results were compared with those obtained from the same training without wb-ems.

Eligibility criteria:
inclusion criteria: * age from 55 to 85 years; * no simultaneous participation in any type of supervised physical activity; * sedentary lifestyle exclusion criteria: * mini-mental state examination (mmse) score of less than 24; * inability to walk for 6 min without assistance; * the presence of a medical condition influencing the cognitive and/or motor functions; * the presence of any counter indication for the utilisation of ems, such as cardiovascular diseases, stents, cardiac pacemakers, and diabetes mellitus, verified by medical certification.

Keywords: wb-electromyostimulation; ems; electrical muscle stimulation; muscle strength; neurodegenerative disease; cardiovascular training
mitochondria and chronic kidney disease

Conditions: Hemodialysis-Induced Symptom; Mitochondrial Diseases

Summary: the overarching goal of this study is to determine the role of chronic kidney disease and the activation of the kallikrein-kinin system during hemodialysis on the development of mitochondrial dysfunction; the investigators will measure mitochondrial function using the gold standard method, 31-phosphorus magnetic resonance spectroscopy. the investigators will test the hypothesis that endogenous bradykinin promotes mitochondrial dysfunction in patients undergoing hemodialysis. the investigators will first perform a randomized, placebo-controlled, double-blind, cross-over study measuring the effect of icatibant (hoe-140), a bradykinin b2 receptor blocker, on mitochondrial function.


Eligibility criteria:
inclusion criteria: * adult patients who have been on maintenance hemodialysis for at least 6 months exclusion criteria: * history of functional transplant less than 6 months prior to study * use of immunosuppressive drugs within 1 month prior to study * history of active connective tissue disease * history of acute infectious disease within one month prior to study * aids (hiv seropositivity is not an exclusion criteria) * history of myocardial infarction or cerebrovascular event within 3 months * advanced liver disease * gastrointestinal dysfunction requiring parental nutrition * active malignancy excluding basal cell carcinoma of the skin * ejection fraction less than 30% * anticipated live donor kidney transplant * pregnancy, breast-feeding or child-bearing potential * history of poor adherence to hemodialysis or medical regimen * subjects with cardiac pacemaker, artificial heart valve, any metallic implant, permanent tattoo, or any retained foreign metallic bodies that are contraindicated in magnetic resonance imaging. * inability to provide consent
a study of an intermittent adt approach with apalutamide monotherapy in participants with mcspc

Conditions: Metastatic Castrate-sensitive Prostate Cancer

Summary: the purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (adt) in participants with metastatic castrate-sensitive prostate cancer (mcspc) who reached a prostate-specific antigen (psa) level \< 0.2 nanograms/millilitres (ng/ml) after 6 months of treatment with apalutamide and adt combination therapy provides non-inferior radiographic progression-free survival (rpfs) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.


Eligibility criteria:
inclusion criteria: * diagnosis of prostate cancer prior to screening with histologically or cytologically confirmed adenocarcinoma of the prostate * for participants not undergoing gender-affirming care: metastatic prostate cancer disease documented by conventional imaging (example, computed tomography \[ct\], magnetic resonance imaging \[mri\], or bone scan) and/or next-generation imaging \[ngi\] demonstrating greater than equal (\>=) 2 distinct extraprostatic sites of metastasis * for participants undergoing gender-affirming care: no evidence of metastasis by either conventional imaging (example, ct, mri, or bone scan) and/or ngi is also acceptable * for participants not undergoing gender-affirming care: testosterone levels \> 50 (ng/dl) nanograms per deciliter at screening, except for those who may have received adt prior to screening. participants are allowed to have received up to 3 months of (adt) androgen-deprivation therapy prior to enrollment * for participants undergoing gender-affirming care: there is no testosterone level requirement for inclusion * have an eastern cooperative oncology group performance status (ecog ps) of 0 or 1. participants with ecog ps 2 or 3 are eligible for the study if the ecog ps score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to prostate cancer or associated therapy * a participant must agree not to plan to conceive a child while enrolled in this study or within 3 months after the last dose of study treatment * must be able to take whole apalutamide tablets by swallowing alone or with another vehicle (example, applesauce) * assigned male at birth, inclusive of all gender identities exclusion criteria: * history of seizure or known condition that has been determined to significantly predispose to seizure per investigator * pelvic lymph nodes as only site of metastasis * known allergies, hypersensitivity, or intolerance to excipients of apalutamide * any of the following within 6 months prior to screening: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant arterial or venous thromboembolic events * gastrointestinal disorder affecting absorption * participants who have undergone a bilateral orchiectomy with the exception of participants who completed this as part of their gender-affirming care or a result of a variation in physical sex development
the correlation between the pulmonary function and intrarenal hemodynamics in 37 t2dm patients in early period

Conditions: Diabetes Mellitus, Type 2

Summary: objective: the main target of this study was to research the early changes in pulmonary function and intrarenal hemodynamics, then research the correlation between the pulmonary function and the renal hemodynamics in type 2 diabetes (t2dm) patients without diabetic kidney disease (dkd). method: 37 t2dm patients (diabetes group) without dkd and 33 healthy people (control group) were choosed to research early changes in pulmonary function and intrarenal hemodynamics, then research the correlation between the pulmonary function and the renal blood flow in t2dm patients, all having normal renal function. the primary endpoints were the pulmonary function parameters (vc%, fvc%, fev1%, pef%, mvv%, tlc%, fev1/fvc%, dlco%, and dlco/va%); the secondary endpoints were the intrarenal hemodynamic (bilateral kidney ri) in bilateral interlobular renal arteries were evaluated using; the tertiary endpoints were the biochemical variables: blood-fat (tc, hdl-c, ldl-c, and tg), renal function parameters (bun, cr, and gfr); in addition, the albumin excrete rate (aer), urinary albumin/creatinine ratio (uacr) were measured.

pulmonary function was measured by spirometer which was provided by jaska corporation in japan, model number: hi-101; ri were measured by logiq 400 md pro series scanner (ge medical systems, milwaukee, wi) using a 3.5-4 mhz vector array transducer

Eligibility criteria:
inclusion criteria: 1) the patients were diagnosed with t2dm according to the guidelines of the american diabetes association ; 2) no smoking history, pulmonary disease, cold, nor pulmonary infection within a fortnight; 3) did not have hepatopathy, nephropathy, hyperuricemia, and gastrointestinal disease; and 4) likely to have good compliance and able to visit our hospital for periodic assessments. exclusion criteria: 1) t1dm, gestation and lactation; 2) renal inadequacy; 3) hypohepatia; 4) intensive care with insulin treatment; 5) the patients combinated with dkd and hypertension (antihypertensive drugs were used); 6) patients with other renal conditions that could affect the hemodynamics, such as urolithiasis, urinary infection, and renal cyst (diameter \> 3 cm); 7) heart failure; 8) cholesterol-lowering drugs can not control the blood-fat ; and 9) use of systemically injected glucocorticoids within 3 months prior to our study.
a rheumatoid arthritis (ra) study treating signs and symptoms of ra in people with ra & receiving methotrexate

Conditions: Rheumatoid Arthritis

Summary: this clinical study is investigating amg 719, an investigational drug, for the treatment of patients who have rheumatoid arthritis and who are taking methotrexate. amg 719 is a drug which is self-injected beneath the skin (similarly to the way insulin is self-injected by diabetics). patients on this study are on study for 28-weeks. they visit the study facility at least 11 times while participating in the study.


Eligibility criteria:
* men or women, at least 18 years of age at screening * diagnosed with rheumatoid arthritis, with a disease duration of at least 24 weeks, receiving methotrexate, and having no recent history of substance or alcohol abuse
il ancillary study of the therapeutic hypothermia after nonshockable cardiac arrest trial.

Conditions: Cardiac Arrest

Summary: cardiac arrest is at present a major cause of mortality as well as a cause of disability for the surviving victims.in europe, every year counts as 300,000 cardiac arrests responsible for 250,000 deaths. thus, less than 20 % of patients discharged home with impaired quality of life associated with symptoms of tiredness, stress, anxiety. the prognosis is related to the initial cardiac rhythm present during the initiation of resuscitation. recent progress in the improvement of mortality and neurological outcome has been achieved over the last decade thanks to the systematic implementation of a period of targeted temperature control between 32 and 34 ° c in patients who benefited from the realization of at least one electrical external shock. there are theoretical and clinical arguments to think that achieving the same way a period of targeted temperature control between 32 and 34 ° c in patients treated for cardiac arrest with a non- shockable rhythm on arrival can also benefit from this procedure. however other arguments are against this hypothesis including an increase in the risk of infection , worsening of the patient's hemodynamic status with no benefit to him. to answer this question, we conduce a randomized multicenter study testing the potential improvement of neurological outcome through this procedure targeted temperature control between 32.5 and 33.5 ° c in these patients. il ancillary study of hyperion trial will determine impact on inflammatory biomarkers of two temperature target for targeted temperature management (33°c or 37°c) after cardiac arrest in non-shockable rhythm.


Eligibility criteria:
inclusion criteria: * cardiac arrest in nonshockable rhythm and * glasgow coma scale score ≤8. in patients receiving sedative therapy at icu admission, the glasgow coma scale score assessed by the emergency physician just before sedative therapy initiation is used. * patient must be randomized in a center which participate in the ancillary study. exclusion criteria: * no-flow time \>10 min (time from collapse to initiation of external cardiac massage); * low-flow time \>60 min (time from initiation of external cardiac massage to return of spontaneous circulation). * major hemodynamic instability (defined as a continuous epinephrine or norepinephrine infusion at a flow rate \>1 μg/kg/min) * time from cardiac arrest to study inclusion \>300 min * moribund patient * child c cirrhosis of the liver * age \<18 years * pregnant or breastfeeding woman * correctional facility inmate * previous inclusion in another randomized clinical trial on cardiac arrest with day-90 neurological outcome as the primary endpoint * patient without health insurance * decision by the patient or next of kin to refuse the study

Keywords: cardiac arrest hypothermia critical care
fusion assessment clinical trial

Conditions: Degenerative Disc Disease

Summary: this is an observational study to assess clinical outcomes in patients who undergo spinal fusion. patients who are already scheduled for spinal fusion will enroll in the study. information about prior therapies will be collected, and then patients will be followed to see how they do after spinal fusion. this study will help researchers better understand the natural course of patients who patients who undergo spinal fusion surgery.


Eligibility criteria:
inclusion criteria: * lumbar ddd * candidate for spinal fusion * provide written informed consent exclusion criteria: * prior lumbar spinal fusion * metabolic bone disease * morbid obesity * systemic infection or active malignancy * pregnancy
free neurovascularized muscle transfer in facial reanimation of long-standing facial palsy patients

Conditions: Facial Paralysis

Summary: the use of free neurovascularized muscles like free latissimus and gracillis muscles for reanimation of long-standing facial palsy patients using the hypoglossal nerve for innervating these muscles

the investigators need to know which of the two muscles is better functionally and aesthetically in facial reanimation of patients with facial paralysis of more than one year duration.

Eligibility criteria:
inclusion criteria: * all patients with facial paralysis more than one year what ever the cause. exclusion criteria: * patients with uncontrolled diabetes.
x-ray computed tomography and blood reactive oxygen species level

Conditions: Healthy

Summary: the clinically widely used x-ray computed tomography examination has a low-grade radiation effect and recently has attracted much attention concerning the possible adverse effects of radiation on human body \[ref. 1-5\]. the radiation is harmful to human tissues and cells mainly because it can interact with water (which makes up to 80% of cells) to generate reactive oxygen species (ros), especially the formation of hydroxyl radicals. so far as we can reach, there is no report concerning the relation between x-ray computed tomography examination and the blood ros concentration. therefore, we wish to conduct this study to clarify if the routinely applied x-ray computed tomography examination may induce a higher concentration of ros in the peripheral blood. study subjects will be participants of health check program at our hospital. the only enrollment condition will be a scheduled x-ray computed tomography examination for either lung (20 cases) or heart (20 cases) of the study subject. another 20 participants receiving health check program without x-ray computed tomography examination will be included as the control group. the formal consent will be delivered to the participants of health check program several days before their admission for health check and will be retrieved before the proceeding of health check. measurements and comparison of ros concentration will be performed in the sampled peripheral blood before and after the performance of x-ray computed tomography examination during a regular health check program. totally 120 blood samples will be collected from included 60 study subjects within 3 months. reactive oxygen species（ros）levels will be measured by a chemiluminescence (cl) analysing system (cld-110, tohoku electronic industrial, sendai, japan).


Eligibility criteria:
inclusion criteria: * participants of health check program at our hospital who will receive a scheduled x-ray computed tomography examination for either lung (20 cases) or heart (20 cases). exclusion criteria: * those whose age are under 50 or above 70 year-olds will be excluded.

Keywords: radiation injuries free radicals reactive oxygen species radiation injury from x-ray computed tomography free radical production blood reactive oxygen species level